期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

卡麦角林治疗泌乳素型垂体瘤的研究进展 被引量：17

下载PDF
导出
摘要 垂体腺瘤是常见的颅内肿瘤,有研究表明发病率约为4/100 000,在30岁年龄段的发病高达30/100 000~50/100000,而泌乳素型垂体瘤是最常见的功能性垂体瘤,在成人垂体瘤患者中约占了40%~45%[1-3],其主要临床表现为高泌素血症以及压迫症状,包括停经、泌乳、不孕不育、流产、视野缺损、视力下降、头痛等。多巴胺受体激动剂（DA）是治疗泌乳素型垂体瘤的首选方式。卡麦角林（Cabergoline,CAB）是一种新型的长效麦角碱衍生物类多巴胺受体激动剂,其通过抑制泌乳素（PRL）的合成与分泌,能够有效降低泌乳素水平,改善性腺功能,缩小肿瘤体积,
作者 杨强 陈晋 刘军
机构地区 重庆医科大学第二附属医院
出处 《中国神经精神疾病杂志》 CAS CSCD 北大核心 2016年第5期311-314,共4页 Chinese Journal of Nervous and Mental Diseases
关键词 泌乳素型垂体瘤 卡麦角林 溴隐亭
分类号 R736.4 [医药卫生—肿瘤]
  • 相关文献

参考文献29

  • 1DALY AF, RIXHON M, ADAM C, at al. High prevalence of pi- tuitary adenomas: a cross-sectional study in the province of Liege Belgium [J]. Clin Endocrinol Metab, 2006, 91 (12): 4769-4775.
  • 2FERNANDEZ A, KARAVITAKI N, WASS JA. Prevalence of pi- tuitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK) [J]. Clinical endocrinology, 2010,72 (3):377-382.
  • 3RAAPPANA A, KOIVUKANGAS J, EBELING T, et al. Inci- dence of pituitary adenomas in Northern Finland in 1992-2007 [J].Clin Endocrinol Metab , 2010,95(9):4268-4275.
  • 4DOS SANTOS NUNES V, EL DIB R, BOQUSZEWSKI CL, et al. Cabergoline versus bromocriptine in the treatment of hyperprolac- tinemia: a systematic review of randomized controlled trials and meta-analysis [J]. Pituitary, 2011,14(3):259-265.
  • 5PRABHAKAR VK, DAVIS JR. Hyperprolactinaemia [J]. BestPract Res Clin Obstet Gynaecol, 2008,22(2):341-353.
  • 6王友伟,马驰原.多巴胺受体激动剂治疗泌乳素瘤的机制及研究进展[J].中华神经外科疾病研究杂志,2013,12(3):286-288. 被引量：16
  • 7ERIC MONSALVES, KYLE JURSACHHKAM, TATENO T, et al. The PI3K/AKT/mTOR pathway in the pathophysiology and treatment of pituitary adenomas [J].Endocrine-Related Cancer, 2014, 21(4):R331-R344.
  • 8DEL DOTrO P, BONUCCELLI U. Clinical pharmacokinetics of cabergoline [J].Clin Pharmacokinet, 2003,42(7):633-645.
  • 9llOLT RI, BARNETT AII, BAILEY CJ. Bromocriptine: old drug, new formulation and new indication [J]. Diabetes Obes Metab, 2010,12 (12):1048-1057.
  • 10VERHELST J, ABS R, MAITER D, VAN DEN BRUEL A, et al. Cabergoline in the treatment of hyperprolaetinemia: a study in 455 patients [J]. Clin Endoerinol Metab, 1999,84(7):2518-2522.

二级参考文献19

  • 1Imran SA, Ur E, Clarke DB. Managing prolactin-secreting adenomas during pregnancy [ J]. Can Fam Physician, 2007, 53 (4) : 653 -658.
  • 2Huda MS, Athauda NB, Teh MM, et al. Factors determining the remission of microprolactinomas after dopamine agonist withdrawal [ J ]. Clin Endocrinol (Oxf), 2010, 72(4): 507-511.
  • 3Sinha S, Shama BS, Mahapatra AK. Microsurgical management of prolactinomas-Clinica and hormonal outcome in a series of 172 cases [J]. Neurol India, 2011,59(4) : 532 -536.
  • 4Massoud F, Serri O, Hardy J, et al. Transsphenoidal adenomectomy for microprolactinomas: 10 to 20 years of follow-up [J]. Surg Neurol, 1996, 45(4) : 341 -346.
  • 5Biswas M, Smith J, Jadon P, et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas [J]. Clin Endocrinol (Oxf), 2005, 63(1): 26- 31.
  • 6dos Santos Nunes V, El Dib R, Boquszewski CL, et al. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis [ J ]. Pituitary, 2011, 14(3): 259-265.
  • 7Colao A, Pivonello R, Di Somma C, et al. Medical therapy of pituitary adenomas: effects on tumor shrinkage [ J]. Rev Endocr Metab Disord, 2009, 10(2): 111-123.
  • 8Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor [J]. Endocr Rev, 2001, 22(6) : 724 -763.
  • 9Oh MC, Aghi MK. Dopamine agonist-resistant prolactinomas [ J]. J Neurosurg, 2011, 114(5): 1369-1379.
  • 10Alberiche Ruano M, Boronat Cortes M, Ojeda Pino A, et al. Acquired resistance to cabergoline: progression from initially responsive micro to macroprolactinoma [ J ]. Pituitary, 2010, 13 (4) : 380 - 382.

共引文献15

同被引文献115

引证文献17

二级引证文献36

中国神经精神疾病杂志
2016年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部